The federal funding law that went into effect this weekend renews a Food and Drug Administration program crucial to drugmakers seeking approval of new medicines.
Renewal of the FDA’s “user fees” program means the agency won’t have to lay off any staff or delay reviews of experimental drugs, a prospect that alarmed the pharmaceutical industry and investors who count on approval decisions.
